Under construction – not a live service
Sign in
Enrolling by invitationPhase 1

Imaging Tumor Oxygen Levels in Children With Soft Tissue Sarcoma

Tests MRI scans that measure tumor oxygen in children with soft tissue sarcoma.

Plain-language title generated from the registry record
Registry title: Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas

Key facts

Where
Toronto, CanadaSee the site
Phase
Phase 1

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and teenagers with a confirmed or suspected sarcoma (rhabdomyosarcoma or another soft tissue sarcoma) who will have chemotherapy before surgery.

Age
6 to 18 years
Sex
All sexes can join.
Disease stage
Confirmed or suspected rhabdomyosarcoma or non-rhabdomyomatous sarcoma, with a part of the tumor outside the bone.
Earlier treatment
Must be a candidate for therapy before surgery: standard chemotherapy, with or without radiation therapy.

Main reasons for not taking part

  • Cannot have an MRI scan (for example a metal foreign body, a pacemaker, or not able to lie still without sedation)
  • Known immunodeficiency, sickle cell disease, collagen vascular disease or another cancer
  • No clinical need for therapy before surgery
  • Chronic lung disease
  • A different diagnosis confirmed after the first suspicion of sarcoma

Read by machine on 12 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 6 and 18 years old?

Source: NCT03054792, who can take part

Where in Canada

  • The Hospital for Sick ChildrenToronto, CanadaNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
The Hospital for Sick Children
Trial code
NCT03054792
Record updated
29 April 2026
Original description
This study will test the feasibility of using novel/existing imaging technologies focused on hypoxia measurements to determine "response to therapy" in pediatric soft tissue sarcomas as a pilot study. Specifically, the investigators will compare the sensitivity of Blood Oxygen Level Dependent [BOLD], Diffusion-Weighted [DW] MRI and Magnetic Resonance Spectroscopy (MRS) with that of conventional MRI to detect measurement changes between the start and completion of neoadjuvant therapy ("response to therapy") in children and adolescents (6-18 years) with suspicion of sarcoma tumors. Clinicians and scientists may use results of the proposed hypoxia-imaging surrogate markers to adjust/modify therapeutic schemes to patients on a personalized basis.Read full original descriptionShow less

Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas: Feasibility Steps Toward Personalized Medicine.

This study will test the feasibility of using novel/existing imaging technologies focused on hypoxia measurements to determine "response to therapy" in pediatric soft tissue sarcomas as a pilot study. Specifically, the investigators will compare the sensitivity of Blood Oxygen Level Dependent [BOLD], Diffusion-Weighted [DW] MRI and Magnetic Resonance Spectroscopy (MRS) with that of conventional MRI to detect measurement changes between the start and completion of neoadjuvant therapy ("response to therapy") in children and adolescents (6-18 years) with suspicion of sarcoma tumors. Clinicians and scientists may use results of the proposed hypoxia-imaging surrogate markers to adjust/modify therapeutic schemes to patients on a personalized basis.

Inclusion: Referred with a confirmed or suspected sarcoma tumor (rhabdomyosarcoma [RMS] or non-rhabdomyomatous sarcoma) presenting with an extra-osseous component; Candidate for neoadjuvant therapy that will consist of standard systemic chemotherapy with or without radiation therapy.

Exclusion: Patients with no clinical indication for neoadjuvant therapy prior to surgery; Patients with a known immunodeficiency/sickle cell disease/collagen vascular disease/another malignancy; Patients with chronic pulmonary disease; Patients with general contraindications for an MRI scan (metal foreign body, pacemaker, inability to tolerate an examination without sedation); Patients with other diagnosis confirmed after initial suspicion of RMS or non-RMS.

ClinicalTrials.gov NCT03054792